ORPH Stock Overview
Open Orphan plc operates as a pharmaceutical service and contract research company.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.20|
|52 Week High||UK£0.48|
|52 Week Low||UK£0.17|
|1 Month Change||-2.22%|
|3 Month Change||-23.85%|
|1 Year Change||-13.91%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||191.18%|
Recent News & Updates
Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year
Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit...
|ORPH||GB Life Sciences||GB Market|
Return vs Industry: ORPH underperformed the UK Life Sciences industry which returned 13.9% over the past year.
Return vs Market: ORPH underperformed the UK Market which returned 11.6% over the past year.
|ORPH Average Weekly Movement||7.1%|
|Life Sciences Industry Average Movement||7.0%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: ORPH is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ORPH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations.
Open Orphan Fundamentals Summary
|ORPH fundamental statistics|
Is ORPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORPH income statement (TTM)|
|Cost of Revenue||UK£39.40m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0045|
|Net Profit Margin||-8.40%|
How did ORPH perform over the long term?See historical performance and comparison
Is Open Orphan undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ORPH (£0.2) is trading above our estimate of fair value (£0.1)
Significantly Below Fair Value: ORPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ORPH is unprofitable, so we can't compare its PE Ratio to the European Life Sciences industry average.
PE vs Market: ORPH is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORPH is overvalued based on its PB Ratio (6.1x) compared to the GB Life Sciences industry average (4.5x).
How is Open Orphan forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: ORPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ORPH's is expected to become profitable in the next 3 years.
Revenue vs Market: ORPH's revenue (19.2% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: ORPH's revenue (19.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORPH's Return on Equity is forecast to be high in 3 years time
How has Open Orphan performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ORPH is currently unprofitable.
Growing Profit Margin: ORPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ORPH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ORPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORPH is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (77.1%).
Return on Equity
High ROE: ORPH has a negative Return on Equity (-13.94%), as it is currently unprofitable.
How is Open Orphan's financial position?
Financial Position Analysis
Short Term Liabilities: ORPH's short term assets (£24.6M) exceed its short term liabilities (£19.0M).
Long Term Liabilities: ORPH's short term assets (£24.6M) exceed its long term liabilities (£540.0K).
Debt to Equity History and Analysis
Debt Level: ORPH has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ORPH's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ORPH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ORPH is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 59.2% per year.
What is Open Orphan current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Open Orphan has no CEO, or we have no data on them.
Experienced Management: ORPH's management team is considered experienced (2.2 years average tenure).
Experienced Board: ORPH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Open Orphan plc's employee growth, exchange listings and data sources
- Name: Open Orphan plc
- Ticker: ORPH
- Exchange: AIM
- Founded: NaN
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£122.431m
- Shares outstanding: 670.86m
- Website: https://www.openorphan.com
Number of Employees
- Open Orphan plc
- 10-12 Alie Street
- 2nd Floor
- Greater London
- E1 8DE
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 21:53|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.